# PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery

> **NCT02804776** · PHASE2 · COMPLETED · sponsor: **National Cancer Centre, Singapore** · enrollment: 15 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT02804776
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-27
- **Primary completion:** 2018-02-21
- **Final completion:** 2018-02-21
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02804776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02804776, "PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02804776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*